The Manufacturer Refund Service (MRS) helps manufacturers to support the integrity and transparency of the 340B Drug Pricing Program.
The Manufacturer Refund Service (MRS) helps support the integrity and transparency of the 340B Drug Pricing Program by providing a standardized and comprehensive approach for manufacturers to efficiently resolve overcharges to covered entities.
Manufacturer restatements of Medicaid best price (BP) or true-ups of provisional 340B ceiling prices for new products can result in 340B ceiling price recalculations, leading to refunds owed to covered entities (CEs) for past 340B purchases.
The 340B Prime Vendor Program (PVP), managed by Apexus, offers the Manufacturer Refund Service (MRS) to manufacturers to manage the resource-intensive, complex task of processing these refunds. MRS was introduced in 2011 at the request of several manufacturers that were looking for a more efficient way to manage the process of refunding CEs for product overcharges.
The 340B PVP MRS facilitates manufacturer refunds to CEs by sending refunds directly to affected facilities, primarily through its PVP Distribution Network. This model can be used by manufacturers with varying product portfolios as a solution for both large and small refunds.
Fully auditable final report with executive summary at project completion as well as detailed weekly progress updates.
The 340B Prime Vendor facilitates CE communication, refund processing, and collecting W-9 tax forms. Most manufacturer refund projects are efficiently completed within 90 days, with initial communications to CEs within 30 days.
To facilitate manufacturer budget planning, the process is outlined prior to the start of the refund project. The 340B Prime Vendor then works with the distributor network and CE relationships, as well as its call center specialists, to process manufacturer refunds efficiently.
The 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties (CMP) Regulation (340B CMP Final Rule) became effective January 1, 2019.
Manufacturers are required to charge CEs no more than the 340B ceiling price for covered outpatient drugs under the 340B statute and their pharmaceutical pricing agreements (PPAs). Manufacturers are expected to restate and issue refunds for overcharges to CEs.
Read about the 340B CMP Final Rule and the OPAIS Pricing System and their impact and best practices for manufacturers.
Manufacturers: Complete the form below to have a team member connect with you.